Clinical Trial Sponsors Should Consider Changing Data Collection Amid COVID-19, US FDA Says

A walking path in a forrest splits and leads two different directions
Sponsors may need to find alternative ways of collecting clinical trial efficacy and safety data due to the impacts of COVID-19. • Source: Shutterstock

More from Clinical Trials

More from R&D